Semi-Supervised Learning for Predicting Multiple Sclerosis.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Sotiris Kotsiantis, Georgia Melagraki, Vassilios Verykios, Aikaterini Sakagianni, John Matsoukas
{"title":"Semi-Supervised Learning for Predicting Multiple Sclerosis.","authors":"Sotiris Kotsiantis, Georgia Melagraki, Vassilios Verykios, Aikaterini Sakagianni, John Matsoukas","doi":"10.3390/jpm15050167","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a propensity to inflict severe neurological disability. Accurate and early prediction of MS progression is extremely crucial for its management and treatment. <b>Methods</b>: In this paper, we compare a number of self-labeled semi-supervised learning methods used to predict MS from labeled and unlabeled medical data. Specifically, we compare the performance of Self-Training, SETRED, Co-Training, Co-Training by Committee, Democratic Co-Learning, RASCO, RelRASCO, CoForest, and TriTraining in different labeled ratios. The data contain clinical, imaging, and demographic features, allowing for a detailed comparison of each method's predictive ability. <b>Results and Conclusions</b>: The experimental results demonstrate that several self-labeling semi-supervised learning (SSL) algorithms perform competitively in the task of Multiple Sclerosis (MS) prediction, even when trained on as little as 30-40% of the labeled data. Notably, Co-Training by Committee, CoForest, and TriTraining consistently deliver high performance across all metrics (accuracy, F1-score, and MCC).</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113346/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a propensity to inflict severe neurological disability. Accurate and early prediction of MS progression is extremely crucial for its management and treatment. Methods: In this paper, we compare a number of self-labeled semi-supervised learning methods used to predict MS from labeled and unlabeled medical data. Specifically, we compare the performance of Self-Training, SETRED, Co-Training, Co-Training by Committee, Democratic Co-Learning, RASCO, RelRASCO, CoForest, and TriTraining in different labeled ratios. The data contain clinical, imaging, and demographic features, allowing for a detailed comparison of each method's predictive ability. Results and Conclusions: The experimental results demonstrate that several self-labeling semi-supervised learning (SSL) algorithms perform competitively in the task of Multiple Sclerosis (MS) prediction, even when trained on as little as 30-40% of the labeled data. Notably, Co-Training by Committee, CoForest, and TriTraining consistently deliver high performance across all metrics (accuracy, F1-score, and MCC).

半监督学习预测多发性硬化症。
背景:多发性硬化症(MS)是一种慢性自身免疫性疾病的中枢神经系统与倾向造成严重的神经功能障碍。准确和早期预测多发性硬化症的进展对其管理和治疗至关重要。方法:在本文中,我们比较了一些用于从标记和未标记的医疗数据中预测MS的自标记半监督学习方法。具体来说,我们比较了Self-Training、SETRED、Co-Training、Co-Training by Committee、Democratic Co-Learning、RASCO、RelRASCO、CoForest和trittraining在不同标记比率下的表现。数据包含临床、影像和人口特征,允许对每种方法的预测能力进行详细的比较。结果和结论:实验结果表明,几种自标记半监督学习(SSL)算法在多发性硬化症(MS)预测任务中表现出竞争力,即使在只有30-40%的标记数据上进行训练。值得注意的是,由Committee、CoForest和trittraining共同进行的培训始终如一地在所有指标(准确性、f1分数和MCC)上提供高性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信